Top

Published in:

07-03-2024 | Chronic Kidney Disease | REVIEWS

The Role of Kynurenine Pathway Metabolites in the Development of Frailty in Older Adults

Author: V. S. Pykhtina

Published in: Advances in Gerontology | Issue 3/2023

Abstract

Frailty is the main geriatric syndrome, which is closely associated with age-related diseases and aging in general. Being considered the main pathogenetic mechanism of aging, low-grade chronic inflammation potentially contributes to increased degradation of the essential amino acid tryptophan through the kynurenine pathway. Active metabolites of the kynurenine pathway, when accumulated, implement their immunomodulatory, pro-inflammatory and cytotoxic properties, thereby supporting and enhancing the aging process. Over the past decade, data have been collected on the role of an unbalanced kynurenine pathway in the pathogenesis of frailty and age-related diseases. This review summarizes clinical and experimental data on the importance of kynurenine pathway analysis as a valuable tool for risk stratification and prognosis of frailty and age-related diseases.

Beard, J.R., Officer, A., de Carvalho, I.A., Sadana, R., Pot, A.M., Michel, J.P., Lloyd-Sherlock, P., Epping-Jordan, J.E., Peeters, G.M.E.E.G., Mahanani, W.R., Thiyagarajan, J.A., and Chatterji, S., The World report on ageing and health: A policy framework for healthy ageing, Lancet, 2016, vol. 387, no. 10033, pp. 2145–2154. PMID: 26520231; PMCID: PMC4848186.https://doi.org/10.1016/S0140-6736(15)00516-4CrossRefPubMed

Fried, L.P., Tangen, C.M., Walston, J., Newman, A.B., Hirsch, C., Gottdiener, J., Seeman, T., Tracy, R., Kop, W.J., Burke, G., and McBurnie, M.A., Cardiovascular Health Study Collaborative Research Group. Frailty in older adults: Evidence for a phenotype, J. Gerontol. A Biol. Sci. Med. Sci., 2001, vol. 56, no. 3, pp. M146–М156. PMID: 11253156.https://doi.org/10.1093/gerona/56.3.m146CrossRefPubMed

Chen, X., Mao, G., and Leng, S.X., Frailty syndrome: An overview, Clin. Interv. Aging, 2014, vol. 9, pp. 433–441. PMID: 24672230; PMCID: PMC3964027.https://doi.org/10.2147/CIA.S45300CrossRefPubMedPubMedCentral

Ottenbacher, K.J., Graham, J.E., Al Snih, S., Raji, M., Samper-Ternent, R., Ostir, G.V., and Markides, K.S., Mexican Americans and frailty: Findings from the Hispanic established populations epidemiologic studies of the elderly, Am. J. Public Health, 2009, vol. 99, no. 4, pp. 673–679. https://doi.org/10.2105/AJPH.2008.143958CrossRefPubMedPubMedCentral

Suhre, K., Shin, S.Y., Petersen, A.K., et al., Human metabolic individuality in biomedical and pharmaceutical research, Nature, 2011, vol. 477, no. 7362, pp. 54–60. PMID: 21886157; PMCID: PMC3832838. https://doi.org/10.1038/nature10354CrossRefPubMed

van der Greef, J., van Wietmarschen, H., van Ommen, B., and Verheij, E., Looking back into the future: 30 years of metabolomics at TNO, Mass. Spectrom. Rev., 2013, vol. 32, no. 5, pp. 399–415. PMID: 23630115.https://doi.org/10.1002/mas.21370CrossRefPubMed

Stone, T.W. and Perkins, M.N., Quinolinic acid: A potent endogenous excitant at amino acid receptors in CNS, Eur. J. Pharmacol., 1981, vol. 72, no. 4, pp. 411–412. PMID: 6268428.https://doi.org/10.1016/0014-2999(81)90587-2

Moroni, F., Tryptophan metabolism and brain function: Focus on kynurenine and other indole metabolites, Eur. J. Pharmacol., 1999, vol. 375, nos. 1–3, pp. 87–100. PMID: 10443567. https://doi.org/10.1016/s0014-2999(99)00196-xCrossRefPubMed

Ying, W., NAD+/NADH and NADP+/NADPH in cellular functions and cell death: Regulation and biological consequences, Antioxid. Redox Signal., 2008, vol. 10, no. 2, pp. 179–206. PMID: 18020963.https://doi.org/10.1089/ars.2007.1672CrossRefPubMed

10.

Jones, S.P., Franco, N.F., Varney, B., Sundaram, G., Brown, D.A., de Bie, J., Lim, C.K., Guillemin, G.J., and Brew, B.J., Expression of the kynurenine pathway in human peripheral blood mononuclear cells: Implications for inflammatory and neurodegenerative disease, PLoS One, 2015, vol. 10, no. 6, p. e0131389. PMID: 26114426; PMCID: PMC4482723.https://doi.org/10.1371/journal.pone.0131389CrossRefPubMedPubMedCentral

11.

Majewski, M., Kozlowska, A., Thoene, M., Lepiarczyk, E., and Grzegorzewski, W.J., Overview of the role of vitamins and minerals on the kynurenine pathway in health and disease, J. Physiol. Pharmacol., 2016, vol. 67, no. 1, pp. 3–19. PMID: 27010891.PubMed

12.

Hardman, D., Aging: A theory based on free radical and radiation chemistry, J. Gerontol., 1956, vol. 11, no. 3, pp. 298–300. PMID: 13332224.https://doi.org/10.1093/geronj/11.3.298CrossRef

13.

Cervenka, I., Agudelo, L.Z., and Ruas, J.L., Kynurenines: Tryptophan’s metabolites in exercise, inflammation, and mental health, Science, 2017, vol. 357, no. 6349, p. eaaf9794. PMID: 28751584.https://doi.org/10.1126/science.aaf9794

14.

Oxenkrug, G., Insulin resistance and dysregulation of tryptophankynurenine and kynurenine–nicotinamide adenine dinucleotide metabolic pathways, Mol. Neurobiol., 2013, vol. 48, no. 2, pp. 294–301. PMID: 23813101; PMCID: PMC3779535.https://doi.org/10.1007/s12035-013-8497-4CrossRefPubMedPubMedCentral

15.

Vujkovic-Cvijin, I., Dunham, R.M., Iwai, S., et al., Dysbiosis of the gut microbiota is associated with HIV disease progression and tryptophan catabolism, Sci. Transl. Med., 2013, vol. 5, no. 193, p. 193ra91. Erratum in: Sci Transl Med. 2017 Nov 8;9(415): PMID: 23843452; PMCID: PMC4094294.https://doi.org/10.1126/scitranslmed.3006438CrossRefPubMedPubMedCentral

16.

Dehhaghi, M., Kazemi Shariat, P.H., and Guillemin, G.J., Microorganisms, tryptophan metabolism, and kynurenine pathway: A complex interconnected loop influencing human health status, Int. J. Tryptophan Res., 2019, vol. 12, p. 1178646919852996. https://doi.org/10.1177/1178646919852996CrossRefPubMedPubMedCentral

17.

Heyes, M.P., Chen, C.Y., Major, E.O., and Saito, K., Different kynurenine pathway enzymes limit quinolinic acid formation by various human cell types, Biochem. J., 1997, vol. 326, pp. 351–356.CrossRefPubMedPubMedCentral

18.

Moffett, J.R. and Namboodiri, M.A., Tryptophan and the immune response, Immunol. Cell Biol., 2003, vol. 81, no. 4, pp. 247–265. PMID: 12848846.https://doi.org/10.1046/j.1440-1711.2003.t01-1-01177.xCrossRefPubMed

19.

Heyes, M.P., Saito, K., Milstien, S., and Schiff, S.J., Quinolinic acid in tumors, hemorrhage and bacterial infections of the central nervous system in children. J. Neurol. Sci., 1995, vol. 133, nos. 1–2, pp. 112–118. PMID: 8583213.https://doi.org/10.1016/0022-510x(95)00164-w

20.

Stone, T.W. and Addae, J.I., The pharmacological manipulation of glutamate receptors and neuroprotection, Eur. J. Pharmacol., 2002, vol. 447, pp. 285–296.CrossRefPubMed

21.

Cozzi, A., Carpenedo, R., and Moroni, F., Kynurenine hydroxylase inhibitors reduce ischemic brain damage: Studies with (m-nitrobenzoyl)-alanine (mNBA) and 3, 4-dimethoxy-[-N-4-(nitrophenyl)thiazol-2yl]-benzen-esulfonamide (Ro 61–8048) in models of focal or global brain ischemia, J. Cereb. Blood Flow Metab., 1999, vol. 19, pp. 771–777.CrossRefPubMed

22.

Okuda, S., Nishiyama, N., Saito, H., and Katsuki, H., 3-Hydroxykynurenine, an endogenous oxidative stress generator, causes neuronal cell death with apoptotic features and region selectivity. J. Neurochem., 1998, vol. 70, no. 1, pp. 299–307. PMID: 9422375.https://doi.org/10.1046/j.1471-4159.1998.70010299.xCrossRefPubMed

23.

Rapisarda, A., Pastorino, S., Massazza, S., Varesio, L., and Bosco, M., Antagonistic effect of picolinic acid and interferon-gamma on macrophage inflammatory protein-1a/b production, Cell Immunol., 2002, vol. 220, p. 7080.CrossRef

24.

Walston, J., McBurnie, M.A., Newman, A., et al., Frailty and activation of the inflammation and coagulation systems with and without clinical comorbidities: Results from the Cardiovascular Health Study, Arch. Intern. Med., 2002, vol. 162, no. 20, pp. 2333–2341.CrossRefPubMed

25.

Varadhan, R., Yao, W., Matteini, A., et al., Simple biologically informed inflammatory index of two serum cytokines predicts 10 year all-cause mortality in older adults, J. Gerontol. A Biol. Sci. Med. Sci., 2014, vol. 69, no. 2, pp. 165–173.

26.

Franceschi, C. and Campisi, J., Chronic inflammation (inflammaging) and its potential contribution to age-associated diseases, J. Gerontol. A Biol. Sci. Med. Sci., 2014, vol. 69, suppl. 1, pp. S4–9.CrossRefPubMed

27.

Gonzalez-Freire, M., de Cabo, R., Studenski, S.A., and Ferrucci, L., The neuromuscular junction: Aging at the crossroad between nerves and muscle, Front. Aging Neurosci., 2014, vol. 6, p. 208.CrossRefPubMedPubMedCentral

28.

Newman, A.B., Gottdiener, J.S., Mcburnie, M.A., Hirsch, C.H., Kop, W.J., Tracy, R., Walston, J.D., and Fried, L.P., Associations of subclinical cardiovascular disease with frailty, J. Gerontol. A Biol. Sci. Med. Sci., 2001, vol. 56, no. 3, pp. M158–М166. https://doi.org/10.1093/gerona/56.3.m158CrossRefPubMed

29.

Soysal, P., Stubbs, B., Lucato, P., Luchini, C., Solmi, M., Peluso, R., Sergi, G., Isik, A.T., Manzato, E., Maggi, S., Maggio, M., Prina, A.M., Cosco, T.D., Wu, Y.-T., and Veronese, N., Inflammation and frailty in the elderly: A systematic review and meta-analysis, Ageing Res. Rev., 2016, vol. 31, pp. 1–8. https://doi.org/10.1016/j.arr.2016.08.006CrossRefPubMed

30.

Hubbard, R.E., O’Mahony, M.S., Savva, G.M., Calver, B.L., and Woodhouse, K.W., Inflammation and frailty measures in older people, J. Cell. Mol. Med., 2009, vol. 13, no. 9B, pp. 3103–3109.https://doi.org/10.1111/j.1582-4934.2009.00733.x

31.

Zhu, Y., Liu, Z., Wang, Y., Wang, Z., Shi, J., Xie, X., Jin, L., Chu, X., and Wang, X., C-reactive protein, frailty and overnight hospital admission in elderly individuals: A population-based study, Arch. Gerontol. Geriatr., 2016, vol. 64, pp. 1–5. https://doi.org/10.1016/j.archger.2015.08.009CrossRefPubMed

32.

Westbrook, R., Chung, T., Lovett, J., et al., Kynurenines link chronic inflammation to functional decline and physical frailty. JCI Insight, 2020, vol. 5, no. 16, p. e136091. PMID: 32814718; PMCID: PMC7455140.https://doi.org/10.1172/jci.insight.136091CrossRefPubMedPubMedCentral

33.

Dugué, P.A., Hodge, A.M., Ulvik, A., et al., Association of markers of inflammation, the kynurenine pathway and B vitamins with age and mortality, and a signature of inflammaging, J. Gerontol. A Biol. Sci. Med. Sci., 2022, vol. 77, no. 4, pp. 826–836. PMID: 34117761. https://doi.org/10.1093/gerona/glab163

34.

Walston, J., Fedarko, N., Yang, H., et al., The physical and biological characterization of a frail mouse model, J. Gerontol. A Biol. Sci. Med. Sci., 2008, vol. 63, no. 4, pp. 391–398.CrossRefPubMed

35.

Valdiglesias, V., Marcos-Pérez, D., Lorenzi, M., Onder, G., Gostner, J.M., Strasser, B., Fuchs, D., and Bonassi, S., Immunological alterations in frail older adults: A cross sectional study, Exp. Gerontol., 2018, vol. 112, pp. 119–126. PMID: 30240849.https://doi.org/10.1016/j.exger.2018.09.010CrossRefPubMed

36.

Marcos-Pérez, D., Sánchez-Flores, M., Maseda, A., Lorenzo-López, L., Millán-Calenti, J.C., Strasser, B., Gostner, J.M., Fuchs, D., Pásaro, E., Valdiglesias, V., and Laffon, B., Frailty status in older adults is related to alterations in indoleamine 2,3-dioxygenase 1 and guanosine triphosphate cyclohydrolase I enzymatic pathways. J. Am. Med. Dir. Assoc., 2017, vol. 18, no. 12, pp. 1049–1057. PMID: 28801236.https://doi.org/10.1016/j.jamda.2017.06.021CrossRefPubMed

37.

Fried, L.P., Tangen, C.M., Walston, J., Newman, A.B., Hirsch, C., Gottdiener, J., Seeman, T., Tracy, R., Kop, W.J., Burke, G., and McBurnie, M.A., Cardiovascular health study collaborative research group, frailty in older adults: Evidence for a phenotype, J. Gerontol. A Biol. Sci. Med. Sci., 2001, vol. 56, no. 3, pp. M146–М156. PMID: 11253156.https://doi.org/10.1093/gerona/56.3.m146CrossRefPubMed

38.

Rockwood, K. and Mitnitski, A., Frailty in relation to the accumulation of deficits, J. Gerontol. A Biol. Sci. Med. Sci., 2007, vol. 62, no. 7, pp. 722–727. PMID: 17634318.https://doi.org/10.1093/gerona/62.7.722CrossRefPubMed

39.

Theou, O., Brothers, T.D., Mitnitski, A., and Rockwood, K., Operationalization of frailty using eight commonly used scales and comparison of their ability to predict all-cause mortality, J. Am. Geriatr. Soc., 2013, vol. 61, no. 9, pp. 1537–1551. PMID: 24028357.https://doi.org/10.1111/jgs.12420CrossRefPubMed

40.

Blodgett, J., Theou, O., Kirkland, S., Andreou, P., and Rockwood, K., Frailty in NHANES: Comparing the frailty index and phenotype, Arch. Gerontol. Geriatr., 2015, vol. 60, no. 3, pp. 464–470.https://doi.org/10.1016/j.archger.2015.01.016

41.

Jang, I.Y., Park, J.H., Kim, J.H., Lee, S., Lee, E., Lee, J.Y., Park, S.J., Kim, D.A., Hamrick, M.W., and Kim, B.J., The association of circulating kynurenine, a tryptophan metabolite, with frailty in older adults, Aging (Albany NY), 2020, vol. 12, no. 21, pp. 22 253–22 265. PMID: 33188590.https://doi.org/10.18632/aging.104179CrossRef

42.

Westbrook, R., Chung, T., Lovett, J., et al., Kynurenines link chronic inflammation to functional decline and physical frailty, JCI Insight, 2020, vol. 5, no. 16, p. e136091. PMID: 32814718; PMCID: PMC7455140.https://doi.org/10.1172/jci.insight.136091CrossRefPubMedPubMedCentral

43.

Dukes, A., Davis, C., El Refaey, M., Upadhyay, S., Mork, S., Arounleut, P., Johnson, M.H., Hill, W.D., Isales, C.M., and Hamrick, M.W., The aromatic amino acid tryptophan stimulates skeletal muscle IGF1/p70s6k/mTor signaling in vivo and the expression of myogenic genes in vitro, Nutrition, 2015, vol. 31, nos. 7–8, pp. 1018–1024. https://doi.org/10.1016/j.nut.2015.02.011

44.

Mangge, H., Stelzer, I., Reininghaus, E.Z., Weghuber, D., Postolache, T.T., and Fuchs, D., Disturbed tryptophan metabolism in cardiovascular disease, Curr. Med. Chem., 2014, vol. 21, no. 17, p. 1931–1937. PMID: 24606499; PMCID: PMC4922792.https://doi.org/10.2174/0929867321666140304105526CrossRefPubMedPubMedCentral

45.

Wokke, J.H., Jennekens, F.G., van der Oord, C.J., Veldman, H., Smit, L.M., and Leppink, G.J., Morphological changes in the human end plate with age, J. Neurol. Sci., 1990, vol. 95, no. 3, p. 291–310. PMID: 2358822.https://doi.org/10.1016/0022-510x(90)90076-yCrossRefPubMed

46.

Addi, T., Dou, L., and Burtey, S., Tryptophan-derived uremic toxins and thrombosis in chronic kidney disease, Toxins (Basel), 2018, vol. 10, no. 10, p. 412. PMID: 30322010; PMCID: PMC6215213.https://doi.org/10.3390/toxins10100412CrossRefPubMed

47.

Hsu, C.N. and Tain, Y.L., Developmental programming and reprogramming of hypertension and kidney disease: Impact of tryptophan metabolism, Int. J. Mol. Sci., 2020, vol. 21, no. 22, p. 8705. PMID: 33218054; PMCID: PMC7698939.https://doi.org/10.3390/ijms21228705CrossRefPubMedPubMedCentral

48.

Rejdak, R., Junemann, A., Grieb, P., Thaler, S., Schuettauf, F., Choragiewicz, T., Zarnowski, T., Turski, W.A., and Zrenner, E., Kynurenic acid and kynurenine aminotransferases in retinal aging and neurodegeneration, Pharmacol. Rep., 2011, vol. 63, no. 6, pp. 1324–1334. PMID: 22358081.https://doi.org/10.1016/s1734-1140(11)70697-1CrossRefPubMed

49.

Al Saedi, A., Chow, S., Vogrin, S., Guillemin, G.J., and Duque, G., Association between tryptophan metabolites, physical performance, and frailty in older persons, Int. J. Tryptophan Res., 2022, vol. 15, p. 11786469211069951. PMID: 35125874; PMCID: PMC8808031.https://doi.org/10.1177/11786469211069951CrossRefPubMedPubMedCentral

50.

Anaya, J.M., Bollag, W.B., Hamrick, M.W., and Isales, C.M., The role of tryptophan metabolites in musculoskeletal stem cell aging, Int. J. Mol. Sci., 2020, vol. 21, no. 18, p. 6670. https://doi.org/10.3390/ijms21186670CrossRefPubMedPubMedCentral

51.

Darlington, L.G., Forrest, C.M., Mackay, G.M., Smith, R.A., Smith, A.J., Stoy, N., and Stone, T.W., On the biological importance of the 3-hydroxyanthranilic acid: Anthranilic acid ratio, Int. J. Tryptophan Res., 2010, vol. 3, pp. 51–59. https://doi.org/10.4137/ijtr.s4282CrossRefPubMedPubMedCentral

52.

Isales, C., Ding, K., Bollag, W., McGee-Lawrence, M., Hill, W., Shi, X., Elsalanty, M., and Hamrick, M., Kynurenic acid a tryptophan metabolite induces bone loss in mice, Innov. Aging, 2018, vol. 2, pp. 100–101. https://doi.org/10.1093/geroni/igy023.377CrossRefPubMedCentral

53.

Okuda, S., Nishiyama, N., Saito, H., and Katsuki, H., Hydrogen peroxide-mediated neuronal cell death induced by an endogenous neurotoxin, 3-hydroxykynurenine, Proc. Natl. Acad. Sci. U.S.A., 1996, vol. 93, no. 22,pp. 12 553–12 558. https://doi.org/10.1073/pnas.93.22.12553CrossRef

54.

Aman, Y., Qiu, Y., Tao, J., and Fang, E., Therapeutic potential of boosting NAD+ in aging and age-related diseases, Transl. Med. Aging, 2018, vol. 2, pp. 30–37.CrossRef

55.

Ding, K., McGee-Lawrence, M.E., Kaiser, H., et al., Picolinic acid, a tryptophan oxidation product, does not impact bone mineral density but increases marrow adiposity, Exp. Gerontol., 2020, vol. 133, p. 110885.CrossRefPubMedPubMedCentral

56.

Forrest, C.M., Mackay, G.M., Oxford, L., Stoy, N., Stone, T.W., and Darlington, L.G., Kynurenine pathway metabolism in patients with osteoporosis after 2 years of drug treatment, Clin. Exp. Pharmacol. Physiol., 2006, vol. 33, pp. 1078–1087.CrossRefPubMed

57.

Apalset, E.M., Gjesdal, C.G., Ueland, P.M., Midttun, Ø., Ulvik, A., Eide, G.E., Meyer, K., and Tell, G.S., Interferon (IFN)-γ-mediated inflammation and the kynurenine pathway in relation to bone mineral density: The Hordaland Health Study, Clin. Exp. Immunol., 2014, vol. 176, pp. 452–460.CrossRefPubMedPubMedCentral

58.

Cason, C.A., Dolan, K.T., Sharma, G., Tao, M., Kulkarni, R., Helenowski, I.B., Doane, B.M., Avram, M.J., McDermott, M.M., Chang, E.B., Ozaki, C.K., and Ho, K.J., Plasma microbiome-modulated indole- and phenylderived metabolites associate with advanced atherosclerosis and postoperative outcomes, J. Vasc. Surg., 2018, vol. 68, no. 5, p. 1552–1562.e7. PMID: 29248242; PMCID: PMC5999545.https://doi.org/10.1016/j.jvs.2017.09.029CrossRefPubMed

59.

Wongpraparut, N., Pengchata, P., Piyophirapong, S., Panchavinnin, P., Pongakasira, R., Arechep, N., Kasetsinsombat, K., and Maneechotesuwan, K., Indoleamine 2,3 dioxygenase (IDO) level as a marker for significant coronary artery disease, BMC Cardiovasc. Disord., 2021, vol. 21, no. 1, p. 353. PMID: 34311709; PMCID: PMC8314527.https://doi.org/10.1186/s12872-021-02140-0CrossRefPubMedPubMedCentral

60.

Bao, Y.S., Ji, Y., Zhao, S.L., Ma, L.L., Xie, R.J., and Na, S.P., Serum levels and activity of indoleamine 2,3-dioxygenase and tryptophanyl-tRNA synthetase and their association with disease severity in patients with chronic kidney disease, Biomarkers, 2013, vol. 18, no. 5, p. 379–385. PMID: 23651343.https://doi.org/10.3109/1354750X.2013.790074CrossRefPubMed

61.

Rhee, E.P., Clish, C.B., Ghorbani, A., et al., A combined epidemiologic and metabolomic approach improves CKD prediction, J. Am. Soc. Nephrol., 2013, vol. 24, no. 8, p. 1330–1338. PMID: 23687356; PMCID: PMC3736702.https://doi.org/10.1681/ASN.2012101006CrossRefPubMedPubMedCentral

62.

Silva, R.E., Baldim, J.L., Chagas-Paula, D.A., Soares, M.G., Lago, J.H.G., Goncalves, R.V., and Novaes, R.D., Predictive metabolomic signatures of endstage renal disease: A multivariate analysis of population-based data, Biochimie, 2018, vol. 152, pp. 14–30. PMID: 29913183.https://doi.org/10.1016/j.biochi.2018.06.009CrossRefPubMed

63.

Goek, O.N., Prehn, C., Sekula, P., Römisch-Margl, W., Döring, A., Gieger, C., Heier, M., Koenig, W., Wang-Sattler, R., Illig, T., Suhre, K., Adamski, J., Köttgen, A., and Meisinger, C., Metabolites associate with kidney function decline and incident chronic kidney disease in the general population, Nephrol. Dial. Transplant., 2013, vol. 28, no. 8, pp. 2131–2138. PMID: 23739151.https://doi.org/10.1093/ndt/gft217CrossRefPubMed

64.

Lee, H., Jang, H.B., Yoo, M.G., Park, S.I., and Lee, H.J., Amino acid metabolites associated with chronic kidney disease: An eight-year follow-up Korean epidemiology study, Biomedicines, 2020, vol. 8, no. 7, p. 222. PMID: 32708997; PMCID: PMC7399801.https://doi.org/10.3390/biomedicines8070222CrossRefPubMedPubMedCentral

65.

Pertovaara, M., Raitala, A., Juonala, M., Lehtimäki, T., Huhtala, H., Oja, S.S., Jokinen, E., Viikari, J.S., Raitakari, O.T., and Hurme, M., Indoleamine 2,3-dioxygenase enzyme activity correlates with risk factors for atherosclerosis: The cardiovascular risk in Young Finns Study, Clin. Exp. Immunol. 2007, vol. 148, no. 1, pp. 106–111. PMID: 17349013; PMCID: PMC1868844.https://doi.org/10.1111/j.1365-2249.2007.03325.xCrossRefPubMedPubMedCentral

66.

Pedersen, E.R., Tuseth, N., Eussen, S.J., Ueland, P.M., Strand, E., Svingen, G.F., Midttun, Ø., Meyer, K., Mellgren, G., Ulvik, A., Nordrehaug, J.E., Nilsen, D.W., and Nygård, O., Associations of plasma kynurenines with risk of acute myocardial infarction in patients with stable angina pectoris, Arterioscler. Thromb. Vasc. Biol., 2015, vol. 35, no. 2, pp. 455–462. PMID: 25524770.https://doi.org/10.1161/ATVBAHA.114.304674CrossRefPubMed

67.

Crepaldi, G. and Allegri, G., Relationship between tryptophan metabolism and vitamin B6 and nicotinamid in aged subjects, Acta Vit. Enzymol., 1975, vol. 29, pp. 140–144.

68.

Rogers, K.S. and Evangelista, S.J., 3-Hydroxykynurenine, 3-hydroxyanthranilic acid, and o-aminophenol inhibit leucine-stimulated insulin release from rat pancreatic islets, Proc. Soc. Exp. Biol. Med., 1985, vol. 178, no. 2, pp. 275–278. PMID: 3881773.https://doi.org/10.3181/00379727-178-42010CrossRefPubMed

69.

Price, J. and Brown, R., Quantitative studies on human urinary metabolites of tryptophan as affected by isoniazid and deoxypyridoxine, J. Clin. Invest., 1957, vol. 36, pp. 1600–1607.CrossRefPubMedPubMedCentral

70.

Zuo, H., Ueland, P.M., Ulvik, A., Eussen, S.J., Vollset, S.E., Nygård, O., Midttun, Ø., Theofylaktopoulou, D., Meyer, K., and Tell, G.S., Plasma biomarkers of inflammation, the kynurenine pathway, and risks of all-cause, cancer, and cardiovascular disease mortality: The Hordaland Health Study. Am. J. Epidemiol., 2016, vol. 183, no. 4, pp. 249–258. PMID: 26823439; PMCID: PMC4753283.https://doi.org/10.1093/aje/kwv242CrossRefPubMedPubMedCentral

71.

Liu, M., Wang, X., Wang, L., Ma, X., Gong, Z., Zhang, S., and Li, Y., Targeting the IDO1 pathway in cancer: From bench to bedside, J. Hematol. Oncol., 2018, vol. 11, no. 1, p. 100. PMID: 30068361; PMCID: PMC6090955.https://doi.org/10.1186/s13045-018-0644-yCrossRefPubMedPubMedCentral

72.

Platten, M., Nollen, E.A.A., Röhrig, U.F., Fallarino, F., and Opitz, C.A., Tryptophan metabolism as a common therapeutic target in cancer, neurodegeneration and beyond, Nat. Rev. Drug Discov., 2019, vol. 18, no. 5, p. 379–401. PMID: 30760888.https://doi.org/10.1038/s41573-019-0016-5CrossRefPubMed

73.

Platten, M., von Knebel Doeberitz, N., Oezen, I., Wick, W., and Ochs, K., Cancer immunotherapy by targeting IDO1/TDO and their downstream effectors, Front. Immunol., 2015, vol. 5, p. 673. PMID: 25628622; PMCID: PMC4290671.https://doi.org/10.3389/fimmu.2014.00673CrossRefPubMedPubMedCentral

74.

Dukes, A., Davis, C., El Refaey, M., Upadhyay, S., Mork, S., Arounleut, P., Johnson, M.H., Hill, W.D., Isales, C.M., and Hamrick, M.W., The aromatic amino acid tryptophan stimulates skeletal muscle IGF1/p70s6k/mTor signaling in vivo and the expression of myogenic genes in vitro, Nutrition, 2015, vol. 31, pp. 1018–1024. https://doi.org/10.1016/j.nut.2015.02.011CrossRefPubMedPubMedCentral

75.

El Refaey, M., Zhong, Q., Hill, W.D., Shi, X.M., Hamrick, M.W., Bailey, L., Johnson, M., Xu, J., Bollag, W.B., Chutkan, N., and Isales, C.M., Aromatic amino acid activation of signaling pathways in bone marrow mesenchymal stem cells depends on oxygen tension, PLoS One, 2014, vol. 9, p. e91108.CrossRefPubMedPubMedCentral

76.

Ding, K.H., Cain, M., Davis, M., et al., Amino acids as signaling molecules modulating bone turnover, Bone, 2018, vol. 115, pp. 15–24.CrossRefPubMedPubMedCentral

77.

Refaey, M.E., McGee-Lawrence, M.E., Fulzele, S., et al., Kynurenine, a tryptophan metabolite that accumulates with age, induces bone loss, J. Bone Miner. Res., 2017, vol. 32, pp. 2182–2193.CrossRefPubMed

78.

Kim, B.J., Hamrick, M.W., Yoo, H.J., Lee, S.H., Kim, S.J., Koh, J.M., and Isales, C.M., The detrimental effects of kynurenine, a tryptophan metabolite, on human bone metabolism, J. Clin. Endocrinol. Metab., 2019, vol. 104, no. 6, pp. 2334–2342. https://doi.org/10.1210/jc.2018-02481CrossRefPubMedPubMedCentral

79.

Lovelace, M.D., Varney, B., Sundaram, G., Lennon, M.J., Lim, C.K., Jacobs, K., Guillemin, G.J., and Brew, B.J., Recent evidence for an expanded role of the kynurenine pathway of tryptophan metabolism in neurological diseases, Neuropharmacology, 2017, vol. 112, pp. 373–388.CrossRefPubMed

80.

Schwarcz, R. and Stone, T.W., The kynurenine pathway and the brain: Challenges, controversies and promises, Neuropharmacology, 2017, vol. 112, pp. 237–247.CrossRefPubMed

81.

Zadori, D., Nyiri, G., Szonyi, A., Szatmari, I., Fulop, F., Toldi, J., Freund, T.F., Vecsei, L., and Klivenyi, P., Neuroprotective effects of a novel kynurenic acid analogue in a transgenic mouse model of Huntington’s disease, J. Neural Transm. (Vienna), 2011, vol. 118, pp. 865–875.CrossRefPubMed

82.

Amaral, M., Levy, C., Heyes, D.J., Lafite, P., Outeiro, T.F., Giorgini, F., Leys, D., and Scrutton, N.S., Structural basis of kynurenine 3-monooxygenase inhibition, Nature, 2013, vol. 496, pp. 382–385.CrossRefPubMedPubMedCentral

83.

Silva-Adaya, D., Perez-De La Cruz, V., Villeda-Hernandez, J., Carrillo-Mora, P., Gonzalez-Herrera, I.G., Garcia, E., Colin-Barenque, L., Pedraza-Chaverri, J., and Santamaria, A., Protective effect of L-kynurenine and probenecid on 6-hydroxydopamine-induced striatal toxicity in rats: Implications of modulating kynurenate as a protective strategy, Neurotoxicol. Teratol., 2011, vol. 33, no. 2, pp. 303–312.CrossRefPubMed

84.

Zádori, D., Nyiri, G., Szonyi, A., Szatmári, I., Fülöp, F., Toldi, J., Freund, T.F., Vécsei, L., and Klivényi, P., Neuroprotective effects of a novel kynurenic acid analogue in a transgenic mouse model of Huntington’s disease, J. Neural Transm. (Vienna), 2011, vol. 118, no. 6, pp. 865–875. PMID: 21194001.https://doi.org/10.1007/s00702-010-0573-6CrossRefPubMed

85.

Shi, H., Enriquez, A., Rapadas, M., et al., NAD deficiency, congenital malformations, and niacin supplementation, N. Engl. J. Med., 2017, vol. 377, no. 6, pp. 544–552. PMID: 28792876.https://doi.org/10.1056/NEJMoa1616361CrossRefPubMed

Title: The Role of Kynurenine Pathway Metabolites in the Development of Frailty in Older Adults
Author: V. S. Pykhtina
Publication date: 07-03-2024
Publisher: Pleiades Publishing
Keyword: Chronic Kidney Disease
Published in: Advances in Gerontology / Issue 3/2023
Print ISSN: 2079-0570
Electronic ISSN: 2079-0589
DOI: https://doi.org/10.1134/S2079057024600216

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin

Prof. Florian Limbourg

Prof. Anoop Chauhan

Developed by: Springer Medicine

Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 3/2023

The Rate of Aging and Its Association with Risk Factors of Cardiovascular Diseases

Demographic Indicators of Probability Models

The Role of the Serotonin Pathway of Tryptophan Metabolism in the Development of Neuroinflammation in Alzheimer’s Disease

Age-Related Changes and Loss of Damage Resistance of Kidney Tissue: The Role of a Decrease in the Number of Kidney Resident Progenitor Cells

Vascular Aging and Telomere Biology: On the Role of Vitamin D3 Deficiency

Mechanisms of Neurocognitive Adaptation during Aging Process

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

At a glance: The STEP trials